RhumbLine Advisers’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $487K | Buy |
48,882
+5,398
| +12% | +$53.8K | ﹤0.01% | 2695 |
|
|
2025
Q1 | $260K | Buy |
43,484
+454
| +1% | +$2.71K | ﹤0.01% | 2973 |
|
|
2024
Q4 | $330K | Buy |
43,030
+1,289
| +3% | +$9.9K | ﹤0.01% | 2935 |
|
|
2024
Q3 | $426K | Sell |
41,741
-3,120
| -7% | -$31.9K | ﹤0.01% | 2809 |
|
|
2024
Q2 | $666K | Buy |
44,861
+3,513
| +8% | +$52.1K | ﹤0.01% | 2470 |
|
|
2024
Q1 | $564K | Buy |
41,348
+1,154
| +3% | +$15.7K | ﹤0.01% | 2592 |
|
|
2023
Q4 | $440K | Sell |
40,194
-28,803
| -42% | -$315K | ﹤0.01% | 2738 |
|
|
2023
Q3 | $756K | Buy |
68,997
+4,089
| +6% | +$44.8K | ﹤0.01% | 2364 |
|
|
2023
Q2 | $859K | Buy |
64,908
+3,661
| +6% | +$48.5K | ﹤0.01% | 2379 |
|
|
2023
Q1 | $834K | Buy |
61,247
+3,025
| +5% | +$41.2K | ﹤0.01% | 2208 |
|
|
2022
Q4 | $1.14M | Buy |
58,222
+1,989
| +4% | +$38.8K | ﹤0.01% | 2063 |
|
|
2022
Q3 | $1.07M | Buy |
56,233
+5,842
| +12% | +$111K | ﹤0.01% | 2102 |
|
|
2022
Q2 | $1.04M | Buy |
50,391
+7,018
| +16% | +$145K | ﹤0.01% | 2128 |
|
|
2022
Q1 | $1.4M | Buy |
43,373
+16,099
| +59% | +$518K | ﹤0.01% | 1988 |
|
|
2021
Q4 | $1.27M | Buy |
27,274
+504
| +2% | +$23.5K | ﹤0.01% | 2111 |
|
|
2021
Q3 | $723K | Buy |
26,770
+610
| +2% | +$16.5K | ﹤0.01% | 2377 |
|
|
2021
Q2 | $671K | Buy |
26,160
+7,594
| +41% | +$195K | ﹤0.01% | 2428 |
|
|
2021
Q1 | $635K | Buy |
18,566
+8,039
| +76% | +$275K | ﹤0.01% | 2384 |
|
|
2020
Q4 | $356K | Buy |
10,527
+1,875
| +22% | +$63.4K | ﹤0.01% | 2593 |
|
|
2020
Q3 | $213K | Buy |
+8,652
| New | +$213K | ﹤0.01% | 2661 |
|